The reported impact of human monoclonal IgM antibody (HAlA) on the mortality rate from Gram-negative bacteraemia aroused considerable interest in its use in Glasgow Royal Infirmary. However, the commercial preparation of HAIA was extremely expensive. With this in mind, the Infirmary's Drugs and Therapeutics Committee introduced a system whereby the commercial preparation of HAlA could be introduced in a controlled fashion, thereby establishing a model which would encourage targeting the prescription of new, highly expensive treatments to appropriate patients. This model provides the clinician with a set of objective criteria to be met before prescribing such a preparation, thus preventing unnecessary increases in the hospital drug budget and justifying using expensive resources.
Introduction
In the USA approximately 175 000 deaths occur annually from sepsis; 50%0 of these are caused by Gram-negative bacteria.' Thus, the reported impact2 of human monoclonal IgM antibody (HA1A) on the mortality rate from Gram-negative bacteria aroused considerable interest in its use in Glasgow Royal Infirmary.
HAlA has been shown in several studies to reduce mortality significantly in septic patients with proven Gram-negative bacteraemia and became commercially available in 1991. Studies also showed no significant difference in the incidence of adverse effects between patients with Gram-negative bacteraemia receiving HAlA and those receiving the placebo.2'3 There were some reports, however, that suggest patients with Gram-positive bacteraemia, given HA1A, have a higher mortality rate than those patients given a placebo. 4 The mechanism of action of HAlA was thought to be related to its ability to either neutralise or enhance the clearance of endotoxin produced by Gram 
Methods
Patients were considered for HA1A ifthere was clinical evidence of serious sepsis with suspected or proven Gram-negative bacteraemia and failure to respond to conventional therapy such as intravenous antibiotics. The consultant responsible for the patient was required initially to seek authorisation for use of HAIA from any one of four nominated senior clinicians. This senior clinician would discuss the individual case with the senior bacteriologist 'on call'. If both the independent clinician and the bacteriologist agreed, authorisation would be given to release the HAlA for administration. To facilitate uniformity of decision-making and ease of subsequent interpretation, the requesting consultant was required to complete a standared HAlA request form giving details of the patient's demographic information together with clinical details including temperature, heart rate, blood pressure, oxygen therapy and saturation, urine output, serum creatinine, bilirubin, transaminases, coagulation screen, white cell count, C-reactive protein, mental state, blood culture and other bacteriology results, antibiotic therapy, date of request, date of administration ofHA1A and names of the authorising doctors. A sepsis score' was calculated for each patient based on a scoring system which quantified the local effects of tissue infection, oral temperature, secondary effects of sepsis and laboratory data (tables 1-4). At a later date, the outcome and date of hospital discharge or death were inserted. This provided an extensive database to analyse the outcome ofthis selection process. Whether or not HAlA was authorised, the completed form had to be returned to the senior bacteriologist who was co-ordinating the study. For convenience, a stock of HAlA together with the authorisation forms were kept in the hospital's Intensive Care Unit. Example ofpatient not authorised to receive HAIA Case C A 61-year-old female with a history of pulmonary thrombo-embolism was admitted with melaena, left iliac fossa peritonism, septicaemic shock and renal failure. Following a prolonged period of resuscitation, she underwent laparotomy and drainage of a retroperitoneal abscess, thought to be perinephric in origin. Her post-operative recovery was complicated and prolonged. However, she survived and was discharged home. During pre-operative resuscitation, a request was made for administration of HA1A. However, at this stage, her sepsis score was only eight, blood cultures were negative, and intravenous antibiotics had just been commenced. On these grounds, authorisation for administration of HA1A was refused.
Discussion
This uncontrolled study was not designed to evaluate the benefits of HAIA. Rather it was designed to assess the effects of a selection procedure which prevented prescribing new, highly expensive treatment for inappropriate patients. There was major mortality in those patients with suspected or proven Gramnegative bacteraemia who received treatment with HA1A, whereas no patient refused HA1A died. Thus the 'authorisation procedure' only allowed the group of patients thought to have a higher mortality rate (from Gram-negative bacteraemia) to be given HAlA and excluded those patients less likely to have Gram-negative sepsis (and hence probably have a lower mortality rate). Authorisation for the administration of HAlA in this model came from any one of four senior clinicians in conjunction with the senior microbiologist 'on call'. This joint decisionmaking allowed both the clinical and bacteriological status of the patient to be taken into account. The fact that all clinicians were aware that such an 'authorisation procedure' existed perhaps encouraged them to think even more seriously as to whether a patient had sufficient evidence of a Gram-negative bacteraemia to merit consideration for HA1A. Furthermore, sufficient detail had to be provided to the authorising senior clinician and bacteriologist to convince them of the need for administration of HA1A.
This approach to the introduction of new, expensive, drugs to a hospital is not designed to be obstructive to clinicians in the treatment of their patients. Indeed, the fact that the three patients who were refused HAlA all survived suggests that this model does not adversely affect care (assuming that HAlA has a beneficial effect). We have no information, however, on the number of patients where this drug would have been considered, or actually administered, in the absence of any constraint as to its use.
On the evidence to date, this model provides the clinician with objective criteria to be met before prescribing a new, unproven, highly expensive medication into an emotive area of Recommendations for introduction of new and expensive anti-microbial therapies * produce objective criteria which must be met before prescribing is allowed * joint decision-making by both clinician and microbiologist * decide outcome measures before prescribing group.bmj.com on June 21, 2017 -Published by http://pmj.bmj.com/ Downloaded from patient care. Furthermore, the approach allows for extensive audit and assessment thereby both preventing unnecessary increases in the hospital drug budget and permitting justification in use of expensive resources where these are approved by independent clinicians (see box).
The study was terminated when HAlA was withdrawn from sale by the manufacturers as it had become apparent that the drug was not associated with a net overall benefit in everyday clinical use.
